VTYX Latest Headlines

LifeSci Capital Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

at www.tipranks.com (Sun, 11-Jan 3:35 AM)

Key deals this week: Merck, Glencore, CrowdStrike, Marvell Technology, Steel Dynamics and more

at seekingalpha.com (Sat, 10-Jan 3:15 PM)

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

at www.tipranks.com (Thu, 8-Jan 12:17 PM)

Eli Lilly (LLY) Buys Ventyx Biosciences in $1.2 Billion Deal

at www.tipranks.com (Thu, 8-Jan 11:00 AM)

Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts

at www.tipranks.com (Thu, 8-Jan 7:44 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ventyx Biosciences (VTYX) and Kamada (KMDA)

at www.tipranks.com (Thu, 8-Jan 7:42 AM)

Hold Rating Maintained on Eli Lilly’s Acquisition of Ventyx Biosciences Amid Limited Upside and NLRP3 Uncertainty

at www.tipranks.com (Thu, 8-Jan 6:56 AM)

Class Action Investigation Targets Ventyx Biosciences After Strategic Shift in Phase 2 Trial Timeline

Market Chameleon (Wed, 7-Jan 10:29 AM)

Hold Rating on Ventyx Biosciences Reflects Limited Upside Amid Eli Lilly All-Cash Acquisition at $14 per Share

at www.tipranks.com (Wed, 7-Jan 8:55 PM)

Eli Lilly to Acquire Ventyx Biosciences in Cash Deal

at www.tipranks.com (Wed, 7-Jan 5:30 PM)

Eli Lilly confirms deal to buy Ventyx Biosciences for $14 a share

at seekingalpha.com (Wed, 7-Jan 5:20 PM)

Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition

at www.benzinga.com (Wed, 7-Jan 12:52 PM)

Biggest stock movers Wednesday: GME, VTYX, MBLY, and more

at seekingalpha.com (Wed, 7-Jan 10:05 AM)

Ventyx Biosciences Faces Legal Investigation Amid Delays in Phase 2 Study—Key Takeaways for Investors

Market Chameleon (Fri, 2-Jan 11:58 AM)

Ventyx Expands Global Phase 2 Study for VTX2735 and Strengthens Advisory Team Ahead of Key Data Milestones

Market Chameleon (Tue, 2-Dec 8:12 AM)

VTX3232 Shows Landmark Reduction in Cardiovascular Inflammation Without Weight Loss Impact: Ventyx Biosciences Phase 2 Results Explained

Market Chameleon (Thu, 23-Oct 9:53 AM)

VTX3232 Achieves 78% Reduction in hsCRP: Phase 2 Study Spotlights New Path in Cardiovascular Risk

Market Chameleon (Thu, 23-Oct 7:06 AM)